LIGAND Pharmaceuticals executive Andrew Reardon sold 5,000 shares across five open-market transactions priced from $283.99 to $288.98 per share. He retained 36,514 shares afterward, giving investors a disclosed view of his remaining position and the scale of the sale relative to his post-transaction holdings.
Key Highlights
- The transactions took place on 3 September 2026.
- All five sales used SEC transaction code S.
- Reardon sold 5,000 shares at prices ranging from $283.99 to $288.98 per share.
LIGAND PHARMACEUTICALS INC (NASDAQ: LGND) executive Andrew Reardon sold 5,000 shares at prices ranging from $283.99 to $288.98 per share. The CLO and secretary completed the transactions across five sales, retaining 36,514 shares afterward.
Five Sales on 3 September 2026
All five transactions occurred on 3 September 2026. Each used SEC transaction code S. The filing identifies Reardon as LIGAND’s CLO and secretary. The reported per-share prices started at $283.99 and extended to $288.98. The combined activity covered 5,000 shares across the five separate transactions. Reardon’s ownership stood at 36,514 shares following the transactions.
FAQs
Q: How many LIGAND Pharmaceuticals shares did Andrew Reardon sell?
A: Andrew Reardon sold 5,000 LIGAND Pharmaceuticals shares across five separate transactions. The reported sale prices ranged from $283.99 to $288.98 per share.
Q: What happened to LGND executive Andrew Reardon’s holdings?
A: Following the reported transactions, Reardon owned 36,514 shares of LIGAND Pharmaceuticals. The filing reports this ownership figure after his five transactions involving 5,000 shares.
Q: When did the LIGAND Pharmaceuticals stock sale occur?
A: The LIGAND Pharmaceuticals stock sale occurred on 3 September 2026. All five transactions took place that day, and each used SEC transaction code S.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.